Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2015

View Archived Issues

Gene therapy from the NEI receives FDA orphan drug designation

DDX3X inhibition inhibits cancer cell proliferation

Biomarkers of cardiovascular risk identified in patients with dysglycemia

Lilly and Merck & Co. expand immuno-oncology collaboration

Thermo Fisher Scientific signs agreement to develop NSCLC universal companion diagnostic

Enumeral Biomedical reports data on its allosteric anti-PD-1 antibodies

Interim phase Ib/II data for ND-L02-s0201

Ignyta and Moffitt Cancer Center collaborate on RXDX-106

Actair house dust mite tablets launched in Japan

NIAID and GSK collaborate on broadly neutralizing antibody strategy for HIV infection

Hapten Sciences plans phase I trial of urushiol vaccine

Study shows potential new indication for miRNA biomarker

FDA approves Ninlaro for multiple myeloma

GSK-1278863 is safe and effective in Japanese, anemic hemodialysis patients

Pfizer discloses TrkA inhibitors

Centaurus BioPharma patents BTK inhibitors

Hyundai Pharmaceutical reports GPR119 agonists

TRIA Bioscience presents synthetic hapten vaccines

Bluebird bio presents improved CARs for T-cell therapies

Eiger BioPharmaceuticals and Celladon to merge

Lupin patents CaSR agonists

FDA grants regular approval to Tafinlar plus Mekinist for melanoma

CTI BioPharma initiates rolling NDA submission for pacritinib in myelofibrosis

European Commission approves Ionsys for acute postoperative pain

Janssen submits NDA for Invokamet XR for type 2 diabetes

Horizon Pharma withdraws Depomed acquisition offer

FDA clears first-in-human study of GeneOne and Inovio's MERS vaccine

EMA committee recommends European approval of Wakix for narcolepsy

Pfizer and Allergan announce merger agreement

Oxaliplatin and capecitabine regimen approved for gastric cancer adjuvant therapy in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...